Abstract
The successful use of 131I-MIBG for the diagnosis and treatment of pheochromocytoma and neuroblastoma has led to its application in patients with carcinoid, another neural crest tumor. The present report describes the scintigraphic findings, in correlation with clinical and biochemical parameters, in 20 patients with histologically proven carcinoids. 131I-MIBG total body scintigraphy was positive in 12 and equivocal in 1 of 19 patients with metastases. The necessity of delayed imaging and the possible advantage of single photon emission tomography for the detection of this tumor are emphasized. The results of 131I-MIBG treatment in five patients with progressive carcinoid metastases are discussed. It is concluded that 131I-MIBG has a role in the work up of patients with proven carcinoid and can be used for palliative treatment of this tumor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clarke SEM, Fogelman I, Lazarus CR, Edwards S, Maisey MN (1987) A Comparison of 131I-MIBG and 99mTc-Pentavalent-DMSA for Imaging Patients with Medullary Cell Carcinoma of the Thyroid. In: Schmidt HAE, Emrich D (eds) Nuklearmedizin — Nuclear Medicine in Research and Practice. Schattauer, Stuttgart
Davis RB, Rosenberg JC (1961) Carcinoid syndrome associated with hyperserotoninaemia and normal 5-hydroxyindoleacetic acid excretion. Am J Med 30:167–174
Feldman JM, Blinder RA, Lucas KJ, Coleman RE (1986) Iodine-131 Meta-iodobenzylguanidine scintigraphy for carcinoid tumors. J Nucl Med 27:1691–1696
Fischer M, Kamanabroo D, Sonderkamp H, Proske T (1984) Scintigraphic imaging of carcinoid tumours with 131I-metaiodobenzylguanidine. Lancet II:165
Goth A (1968) Medical Pharmacology. CV Mosby, St. Louis, p 168
Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR (1985) Total body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma. Diagn Imag Clin Med 54:21–27
Hoefnagel CA, den Hartog Jager FCA, van Gennip AH, Marcuse HR, Taal BG (1986) Diagnosis and treatment of a carcinoid tumor using I-131-meta-iodobenzylguanidine. Clin Nucl Med 11:150–152
Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR (1987a) Radionuclide diagnosis and therapy of neural crest tumors using I-131-meta-iodobenzylguanidine. J Nucl Med 28:308–314
Hoefnagel CA, Voûte PA, de Kraker J, Klumper A (1987b) Single photon emission tomography using I-131-MIBG in neural crest tumors. In: Schmidt HAE, Emrich D (eds) Nuklearmedizin — Nuclear Medicine in Research and Practice. Schattauer, Stuttgart
Lynn MD, Shapiro B, Sisson JC, Swanson DP, Mangner TJ, Wieland DM, Meyers LJ, Glowniak JV, Beierwaltes WH (1984) Portrayal of pheochromocytoma and normal adrenal medulla by m-[123I]-iodobenzylguanidine: concise communication. J Nucl Med 25:436–440
Oates JA, Butler TS (1967) Pharmacologic and endocrine aspects of carcinoid syndrome. Adv Pharmacol Chemother 5:109
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585
Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH, Thompson NW (1981) Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12–17
Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG, Wieland DM (1984) Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 25:197–206
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoefnagel, C.A., den Hartog Jager, F.C.A., Taal, B.G. et al. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13, 187–191 (1987). https://doi.org/10.1007/BF00256489
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00256489